Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China

NCT01812096 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma Proved by Laboratory Tests

Interventions

OTHER: Subcutaneous bortezomib
OTHER: Intravenous bortezomib

Sponsor

The First Affiliated Hospital of Soochow University